Angiotensin ii is a vasoconstrictor. It is available as injection for intravenous use. MedsAcross supplies Angiotensin ii for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
1. INDICATIONS AND USAGE GIAPREZA increases blood pressure in adults with septic or other distributive shock. GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.
Source: US FDA prescribing information
12.1. Mechanism of Action Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca 2+ /calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.
Source: US FDA prescribing information
2. DOSAGE AND ADMINISTRATION Dilute GIAPREZA in 0.9% sodium chloride prior to use. See Full Prescribing Information for instructions on preparation and administration of injection. Diluted solution may be stored at room temperature or under refrigeration and should be discarded after 24 hours. GIAPREZA must be administered as an intravenous infusion. Start GIAPREZA intravenously at 20 nanograms (ng)/kg/min. Titrate as frequently as every 5 minutes by increments of up to 15 ng/kg/min as needed. During the first 3 hours, the maximum dose should not exceed 80 ng/kg/min. Maintenance dose should not exceed 40 ng/kg/min. Doses as low as 1.25 ng/kg/min may be used. 2.1. Preparation Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Source: US FDA prescribing information
4. CONTRAINDICATIONS None. None
Source: US FDA prescribing information
5. WARNINGS AND PRECAUTIONS There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.
Source: US FDA prescribing information
6. ADVERSE REACTIONS The most common adverse reactions reported in greater than 10% of GIAPREZA treated patients were thromboembolic events. 6.1. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. ATHOS-3 The safety of GIAPREZA was evaluated in ATHOS-3. Patients in ATHOS-3 were receiving other vasopressors in addition to GIAPREZA or placebo, which were titrated to effect on mean arterial pressure (MAP). Table 1 summarizes adverse reactions with an incidence of at least 4% among patients treated with GIAPREZA and with a rate of at least 1.5% higher with GIAPREZA than with placebo.
Source: US FDA prescribing information
7. DRUG INTERACTIONS Angiotensin converting enzyme (ACE) inhibitors ACE inhibitors may increase response to GIAPREZA. Angiotensin II Receptor Blockers (ARB) ARBs may reduce response to GIAPREZA. 7.1. Angiotensin Converting Enzyme (ACE) Inhibitors Concomitant use of angiotensin converting enzyme (ACE) inhibitors may increase the response to GIAPREZA. 7.2. Angiotensin II Receptor Blockers (ARB) Concomitant use of angiotensin II receptor blockers (ARBs) may decrease the response to GIAPREZA.
Source: US FDA prescribing information
GIAPREZA vials should be stored in the refrigerator between 2°C to 8°C (36°F to 46°F). Discard prepared diluted solution after 24 hours at room temperature or under refrigeration.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Angiotensin ii, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Angiotensin ii 2.5 mg/1 mL injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Giapreza 0.5 mg/1 mL injectionIntravenous Cold chain | La Jolla Pharmaceutical | US FDA | Available on request |
| Giapreza 2.5 mg/1 mL injectionIntravenous Cold chain | La Jolla Pharmaceutical | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 3 presentations of Angiotensin ii and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Angiotensin ii, including Giapreza.
Yes. The US FDA first approved Angiotensin ii on 21 December 2017, according to Drugs@FDA.
Yes. Angiotensin ii has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Angiotensin ii must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Angiotensin ii is classified under ATC code C01CX09 (Angiotensin ii).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.